CJC-1295 for Longevity: Evidence Summary, Off-Label Status, and Clinical Reality

Is CJC-1295 approved for anything?

No. CJC-1295 is not an FDA-approved drug. In December 2024 FDA looked for approved products containing any form of CJC-1295 in Australia, Belgium, Canada, Denmark, France, Germany, Ireland, Italy, Japan, Norway, Spain and the United Kingdom, found none, and found none authorised by the European Medicines Agency [1]. It is an investigational long-acting analogue of growth hormone-releasing hormone (GHRH), developed by ConjuChem Biotechnologies of Montreal and first described in 2005 [1][6].

FDA describes two forms: CJC-1295, a 29-amino-acid GHRH analogue, and CJC-1295 DAC, the same peptide carrying an extra maleimidopropionic acid-lysine unit at the C-terminal end that lets it bind albumin in blood and last far longer [1]. The preclinical paper that identified it describes a tetrasubstituted form of GHRH(1-29) with that added lysine unit, detectable in rat plasma beyond 72 hours [6].

It is sometimes marketed as an enhanced sermorelin. Sermorelin was once an approved drug (Geref, withdrawn in 2009); CJC-1295 was never approved [1].

What did the human studies actually measure?

The three published human studies are Teichman 2006, Ionescu and Frohman 2006 and Sackmann-Sala 2009. All used the DAC form and all enrolled healthy volunteers; FDA found no study of any form of CJC-1295 in people with a disease [1].

Teichman and colleagues ran two randomised, placebo-controlled, double-blind, ascending-dose trials lasting 28 and 49 days in healthy adults aged 21 to 61, with single doses in the first study and two or three weekly or biweekly doses in the second [5]. After a single injection, mean plasma GH rose 2- to 10-fold for 6 days or more and mean IGF-I rose 1.5- to 3-fold for 9 to 11 days; the estimated half-life was 5.8 to 8.1 days; after multiple doses IGF-I stayed above baseline for up to 28 days [5]. FDA counted 35 treated volunteers and 7 on placebo in the first study [1].

Ionescu and Frohman gave healthy men aged 20 to 40 a single injection of 60 or 90 micrograms/kg and sampled blood every 20 minutes overnight, before and one week after [7]. Pulse frequency and pulse size were unchanged, but trough GH rose 7.5-fold (P<0.0001), mean GH rose 46% (P<0.01) and IGF-I rose 45% (P<0.001), with no difference between the two doses [7].

In both of these studies the main outcomes were GH and IGF-I levels, not body composition, strength, disease or survival. Higher hormone levels are a laboratory finding, not a demonstrated health benefit.

Does raising GH and IGF-I point toward longer life?

The biology does not run in one direction. Bartke's review notes that the age-related fall in GH has been read three different ways: as a symptom of neuroendocrine ageing, as a cause of changed body composition, and as protection from cancer and other chronic disease [8]. Mice lacking GH signals show impressive extension of longevity, and survival to extreme old age in people has been associated with reduced GH and IGF-I signalling [8]. The same review states that raising GH into the supranormal (pathological) range is associated with increased disease risk and reduced life expectancy, and that the widely advertised use of GH as an anti-ageing agent has produced disappointing results with few documented benefits and many troublesome side effects [8].

In a cohort of Ashkenazi Jewish centenarians, their offspring and matched controls, heterozygous IGF1 receptor mutations were over-represented among female centenarians and were associated with high serum IGF-I alongside reduced receptor activity in transformed lymphocytes [9]. These are associations in free-living populations, not tests of any peptide.

Regulatory status in the United States

FDA's page on bulk substances that may present significant safety risks, with content dated 22 April 2026, lists CJC-1295 in its nominated-but-withdrawn table: it had been placed in category 2 but came off when the nominators withdrew [10]. FDA's stated concerns remain posted: possible immunogenicity for certain routes, impurity and characterisation problems, serious adverse events including increased heart rate and systemic vasodilatory reaction, and limited clinical data [10].

CJC-1295 appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated 14 May 2026) and is not on the list for outsourcing facilities (updated 21 March 2025). It is not a component of an approved drug and has no USP monograph, so the category 1 policy does not apply to it [2][3].

In December 2024 FDA's reviewers proposed that none of the CJC-1295 forms be added to the pharmacy bulks list. On 4 December 2024 the Pharmacy Compounding Advisory Committee voted 0 yes and 13 no on the free base, 1 yes and 12 no on the acetate, and 0 yes and 13 no on each of the three DAC forms [11].

CJC-1295 is not among the six peptides covered by HHS's October 2026 draft enforcement-discretion policy, which names BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 [12]. FDA notes that CJC-1295 sold online is mostly labelled research use only, including blends with ipamorelin and other GH-releasing peptides, and that research-use-only products are not approved drugs [1].

What the trials reported as side effects

In the Teichman trials, FDA's summary lists injection-site reactions in about 70% of treated subjects in study 1 and in all treated subjects in study 2; headache in 63% versus 14% on placebo in study 1; flushing, warmth and transient low blood pressure in about 30% of treated subjects in study 1; transient diarrhoea; and transient dizziness with low blood pressure in two subjects. Most events were more common at the higher doses of 125 or 250 micrograms/kg, and no serious adverse reactions were reported [1][5].

In the Ionescu and Frohman study there were no serious adverse events, with dose-dependent increases in heart rate and transient injection-site redness and tenderness [1].

FDA noted that elevating GH and IGF-I carries the risks listed on approved growth hormone labels, for example glucose intolerance and diabetes, fluid retention and tumour growth concerns. It also said the CJC-1295 studies were short, small and mostly single-dose, so long-term safety is unknown [1].

The 2006 HIV lipodystrophy trial

One trial in HIV-associated visceral obesity (NCT00267527) was listed on ClinicalTrials.gov and terminated [1]. Separately, FDA's briefing states that ConjuChem withdrew CJC-1295 DAC from clinical trials in 2006 after a participant in a phase 2 trial in HIV lipodystrophy, which enrolled 192 people, died. FDA cites anecdotal news reports: the person had chest discomfort 2 hours after an 11th weekly dose, an ECG showed an acute heart attack, and the attending physician's most likely explanation was undiagnosed coronary artery disease with plaque rupture. The data were never published, so a causal link is neither shown nor excluded [1].

Doses used in the studies

There is no approved dose. In the human studies of the DAC form in healthy adults, doses were single subcutaneous injections of about 30 to 250 micrograms/kg, or two to three doses given weekly or every two weeks [1][5]. Those are the doses that were tested, not recommendations.

Sport

WADA's 2026 Prohibited List names CJC-1295 and CJC-1293 in S2.2.4 as growth hormone-releasing hormone analogues, prohibited at all times in and out of competition, and classifies S2 substances as non-Specified Substances. The 2027 List, in force from 1 January 2027, names it too [4][13].